Abcellera Biologics is trading 4.34% up at $14.52 after JPMorgan initiated coverage with an Overweight rating and a $17 target, cited as the immediate pre-market trigger.
- The September 29 report cited upcoming ABCL635 Phase 2 data presentation as pipeline context, not a new announcement that day.
- Major indices were essentially flat; broad-market strength does not explain the move.
- Current volume was unavailable, limiting assessment of trading activity.